PUBLIC COMPANY
saveVectorY Therapeutics Inc
updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- This week in charts: Brain drugs are back on venture capitalists’ mindsFive neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.biopharma_dive · 2d ago
- VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseasesVectorY Therapeutics added €74.5 million ($83.5 million) to its Series A to fund a gene therapy that makes antibodies in the brain. The biotech’s lead asset VTx-002 is in aendpoints · 4d ago
comments(0)
5-min edit window · permanent after that